Andrea Flynn | Head of Investor Relations |
Bruce Cozadd | Chief Executive Officer |
Renée Galá | Chief Financial Officer |
Dan Swisher | President |
Rob Iannone | Executive Vice President of R&D and Chief Medical Officer |
Kim Sablich | Executive Vice President, General Manager of North America |
Phil Jochelson | Neuroscience Therapeutic Head |
Jed Black | Senior Vice President of Sleep and Neuroscience |
Jessica Fye | JPMorgan |
Ami Fadia | SVB Leerink |
Jason Gerberry | Bank of America |
Ken Cacciatore | Cowen |
Balaji Prasad | Barclays |
Randall Stanicky | RBC Capital Markets |
Gary Nachman | BMO Capital Markets |
David Amsellem | Piper Sandler |
Greg Gilbert | Truist Securities |
David Risinger | Morgan Stanley |
Brandon Folkes | Cantor Fitzgerald |
Esther Rajavelu | UBS |
David Steinberg | Jefferies |
Annabel Samimy | Stifel |
Graig Suvannavejh | Goldman Sachs |
Akash Tewari | Wolfe Research |
Ronny Gal | Bernstein |
Hello and welcome to the Jazz Pharmaceuticals Full Year and Fourth Quarter 2020 Financial Results Earnings Conference Call.
Following an introduction from the company, we will open the call to questions. I will now turn the call over to Andrea Flynn, Head of Investor Relations at Jazz Pharmaceuticals.
You may begin.
Thank you.